Respiratory syncytial virus, or RSV, is the leading cause of bronchiolitis, a viral infection of the small airways that sends hundreds of thousands of infants to hospitals across Europe each winter. For decades, pediatricians had little to offer beyond supportive care, since a previous antibody product, palivizumab, was reserved for high-risk infants because of its high cost and the need for monthly injections. Nirsevimab changed that calculus. A single dose provides protection lasting at least five months, covering an entire RSV season, and clinical trials demonstrated strong efficacy against medically attended lower respiratory tract infection in healthy term and preterm infants alike.

When nirsevimab finally became available in Europe in late 2023, national and regional health authorities adopted it at different speeds and with different strategies. Some countries launched universal immunization programs targeting all infants entering their first RSV season, while others restricted initial campaigns to infants born during or just before the season, and a few had no program at all during the study window. This patchwork of implementation created an unintended natural experiment, and a large consortium of European pediatric emergency researchers seized the opportunity to measure what happened.

The research team, led by Léa Lenglart and Naim Ouldali with the EPISODES Study Group, assembled routinely collected data from 27 pediatric emergency departments spanning 12 European countries, covering the period from January 2018 through March 2024. They included every case of bronchiolitis diagnosed in infants younger than 12 months, yielding a total of 107,088 episodes. Regions were classified as intervention or control depending on whether nirsevimab had been implemented, and immunization coverage figures were drawn from official regional reports. Urinary tract infections in the same age group served as a control outcome, a standard technique to detect whether observed changes reflect a real intervention effect or some unrelated shift in emergency department attendance.

The analytical approach was a controlled interrupted time-series design, a method well suited to evaluating population-level interventions introduced at a known point in time. The models accounted for underlying seasonality and pre-existing temporal trends, allowing the researchers to estimate how much of the change in monthly bronchiolitis cases during the intervention period, from October 2023 through March 2024, could be attributed to the antibody program rather than to the ordinary rhythm of winter epidemics. Estimates were stratified by age group, separating infants aged 0 to 3 months, who face the highest risk of severe disease, from those aged 3 to 12 months.

The results were striking in both their magnitude and their heterogeneity. Reductions in bronchiolitis visits ranged from essentially no change, with one estimate of plus 0.6 percent, to a remarkable 61 percent decline, with a confidence interval stretching from minus 67.8 to minus 35.2 percent. Infants in the youngest age band generally showed the largest reductions, consistent with the biology of RSV, since the highest rates of hospitalization and intensive care admission occur in the first months of life. Meanwhile, bronchiolitis trends in control regions without nirsevimab programs remained stable, and urinary tract infection visits showed no comparable decline, strengthening the argument that the observed reductions were tied to the immunization campaigns rather than a general drop in emergency presentations.

Perhaps the most consequential finding was the strength of the statistical relationship between coverage and benefit. Across regions and age groups, the correlation between nirsevimab coverage and the percentage reduction in bronchiolitis visits was negative and pronounced, with a correlation coefficient of minus 0.86 and a p-value of 0.001. In practical terms, regions that immunized a larger share of their infant population saw proportionally larger drops in emergency department visits. The relationship held across both age strata, suggesting that the antibody’s protective effect translated into population benefit wherever it reached enough infants, whether they were immunized at birth during the season or through catch-up campaigns targeting older babies.

Why did coverage differ so much across Europe? The study points to implementation choices as the decisive variable. Countries and regions that embedded nirsevimab into routine newborn care, offering the dose in maternity wards before discharge, achieved far higher uptake than those relying on later appointments or opportunistic vaccination during other visits. Administrative hurdles, supply constraints, differences in eligibility criteria, and varying levels of parental and clinician acceptance all likely contributed. The authors emphasize that the antibody’s intrinsic efficacy, already demonstrated in randomized trials, was never in question; what varied was the fraction of the infant population that actually received it in time to be protected when the virus arrived.

The researchers are careful about the limits of their design. As an ecological study, it examines populations rather than individuals, so causality cannot be definitively inferred. Unmeasured regional differences, such as changes in testing practices, health-seeking behavior, viral circulation intensity, or concurrent public health measures, may have contributed to some of the observed variability. The interrupted time-series models adjust for seasonality and trend, and the stability of control outcomes argues against simple artifacts, but the authors acknowledge that residual confounding remains possible. Still, the consistency of the findings across 27 departments, multiple countries, and two age groups, together with the tight coverage-response relationship, makes a compelling case that immunization coverage was a key driver of the reductions.

The implications for health policy are immediate. RSV prevention has entered a new era, with nirsevimab programs now expanding and maternal RSV vaccines adding another layer of protection for newborns. This study demonstrates that the public health return on these interventions depends not only on the biology of the product but on the machinery of delivery. Regions that achieved high coverage among both season-born and out-of-season infants reaped reductions in bronchiolitis visits of a scale rarely seen for a respiratory disease, easing pressure on emergency services during the busiest weeks of the winter. For health authorities weighing how to structure their own programs, the European experience of 2023–2024 offers a clear lesson: the fastest, broadest, and earliest possible reach into the infant population is what converts a highly effective antibody into a visible decline in disease. As nirsevimab programs mature and additional seasons of data accumulate, researchers will be watching to see whether the coverage-response relationship holds, whether protection extends to severe outcomes such as intensive care admission, and whether the substantial regional variability in implementation narrows as systems learn from one another.

Subject of Research: Association between nirsevimab immunization coverage and reductions in infant bronchiolitis emergency department visits across 12 European countries

Article Title: Association between nirsevimab coverage and pediatric emergency department visits for bronchiolitis in 12 European countries: An interrupted time-series analysis

Article References: Lenglart, L., Titomanlio, L., Alberti, I., Almeida, L., Aupiais, C., Akyüz Özkan, E., Barrett, M., Basmaci, R., Birbilen, A., Borensztajn, D., Schönenberger, C. B., Bressan, S., Buonsenso, D., Campos, T., Castanhinha, S., Chiaretti, A., Claret, G., De Zan, F., Durnin, S., … the EPISODES Study Group (2026). Association between nirsevimab coverage and pediatric emergency department visits for bronchiolitis in 12 European countries: An interrupted time-series analysis. PLOS Medicine, 23(9), e1005223. https://doi.org/10.1371/journal.pmed.1005223

Image Credits: AI Generated

DOI: 10.1371/journal.pmed.1005223

Keywords: nirsevimab, RSV, bronchiolitis, infants, pediatric emergency departments, immunization coverage, interrupted time-series, Europe, PLOS Medicine, monoclonal antibody, respiratory syncytial virus, public health

Scalp vein catheters are among the most common tools in neonatal and pediatric medicine. Because the veins of an infant’s scalp are superficial, visible, and relatively easy to puncture, nurses and doctors frequently use them to deliver fluids, antibiotics, and nutrition to babies whose limb veins are too small or too mobile to cannulate reliably. The catheters themselves are deliberately soft and thin, a design choice that protects delicate vessel walls but also makes the devices vulnerable. Infants move constantly, cry, flex their necks, and rub their heads, and all of that motion places repeated mechanical stress on a tube that may be only fractions of a millimeter thick.

Catheter breakage during removal is an extremely rare complication, but when it happens, the consequences can be serious. Once a fragment detaches, it becomes an intravascular foreign body. The vessel wall, recognizing the plastic as foreign material, begins to encapsulate it in fibrous tissue, and the fragment can soften, migrate with blood flow, and in the worst cases travel toward the central circulation and cause venous embolism. For parents, the discovery that a piece of a catheter has vanished into their child’s body is deeply distressing, and the medical team faces an equally difficult problem: how to find and extract something small, flexible, and mobile inside a body that is itself very small.

The three cases described by the team, led by surgeons at Beijing Children’s Hospital of Capital Medical University together with colleagues at Inner Mongolia Maternal and Child Health Care Hospital, illustrate exactly why. All three infants had already undergone failed removal attempts at other facilities before reaching the reporting hospital. In the first case, two separate operations within three days both failed to extract the catheter fragment. In the second and third cases, the fragments had been left in place far longer, remaining in the children’s bodies for nine months and five years respectively, and in both instances the plastic had migrated away from the original scalp puncture site down to the neck.

Those timelines matter. A fragment that sits in a vein for months or years becomes progressively more encapsulated, more embedded in surrounding tissue, and harder to distinguish from normal anatomy. Migration compounds the difficulty, because the surgeon who plans an incision based on where the catheter entered the body may find nothing there. The authors argue that this is precisely why blind exploration, cutting into the body and searching by feel or by plain X-ray alone, should be avoided. Each failed attempt adds scarring, extends anesthesia time, and increases the emotional and physical toll on an infant who cannot understand what is happening.

The alternative the team proposes is a multimodal localization strategy built around three-dimensional computed tomography. Modern CT scanners acquire thin-slice volumetric data, and reconstruction software can process that data in several complementary ways. Multi-planar reconstruction allows the radiologist and surgeon to scroll through the anatomy in axial, coronal, and sagittal planes, tracing the catheter fragment’s course vessel by vessel. Volume rendering goes further, generating a three-dimensional model in which bone, soft tissue, and the radiopaque fragment can be viewed together and rotated on screen, so that the fragment’s position can be understood in true spatial relation to landmarks such as the clavicle, the cervical vertebrae, and the great vessels of the neck.

Three-dimensional reconstruction alone, however, tells the surgeon where the fragment is inside the imaging dataset, not where to put the scalpel on the living patient. The second half of the strategy is body surface localization, in which the coordinates established on the CT model are translated onto the child’s skin before the operation begins. By projecting the fragment’s reconstructed position onto external reference points, the team marks an entry approach that minimizes the distance between incision and target. Complementary ultrasound verification adds real-time confirmation: ultrasound carries no radiation dose, can be repeated at the bedside, and lets the team confirm that the fragment has not shifted between the imaging study and the moment of surgery, which is particularly valuable in a population of patients who cannot hold still on command.

With the fragment localized in three dimensions and verified on the surface, the surgical removal itself becomes a targeted, minimally invasive procedure rather than an exploratory hunt. The reported cases support the approach: after the failures elsewhere, precise preoperative localization enabled successful extraction in these infants. The authors conclude that prompt surgical intervention is vital once a catheter fracture is recognized, and that the combination of 3D-CT reconstruction as the primary tool with ultrasound as a verification modality is the key to ensuring successful, minimally invasive treatment. The study was approved by the Ethics Committee of Beijing Children’s Hospital, and written informed consent for publication was obtained from the patients’ parents.

The broader lesson extends beyond this single rare complication. Peripheral intravenous catheters are placed millions of times a year in children worldwide, and the overwhelming majority of placements and removals proceed without incident. But the small subset of cases in which a fragment is retained demonstrates a principle that applies across pediatric surgery: in a small body, precision is not a luxury but a prerequisite. Imaging that would be helpful in an adult is often decisive in an infant, where a few millimeters of error can mean the difference between a short operation and a second failed one. The authors also situate their cases within the existing literature on intravascular foreign bodies, reinforcing that the management algorithm, recognize the fracture, image it in three dimensions, verify with ultrasound, mark the surface, and operate once, is generalizable.

For clinicians, the practical takeaways are concrete. When a catheter breaks during removal, the fragment should be assumed to be mobile and the child should be kept calm and still to reduce the chance of further migration. Prompt cross-sectional imaging should follow, with 3D reconstruction requested rather than plain radiographs alone, since a thin plastic tube can be difficult to see on a two-dimensional film and its depth cannot be judged from it at all. And when the first attempt fails, the answer is not another blind attempt but a step up in localization technology. For parents, the message is sobering but ultimately reassuring: although catheter fracture is frightening, it is rare, it is treatable, and with modern imaging the piece of plastic that once seemed lost can be found with millimeter accuracy and removed through a small, precisely planned incision, sparing a child the repeated operations that the three infants in this report had endured before reaching the team that finally got it right.

Subject of Research: Retained fractured scalp vein catheter fragments in infants and their precise preoperative localization and surgical removal using 3D-CT reconstruction and body surface localization

Article Title: Precise removal of fractured scalp vein catheters in infants using 3D-CT reconstruction and body surface localization: case reports and literature review

Article References: Sun, J., Zhang, J., Zhao, Y., Sun, D., Wang, X., & Huang, J. (2026). Precise removal of fractured scalp vein catheters in infants using 3D-CT reconstruction and body surface localization: case reports and literature review. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07637-1

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07637-1

Keywords: scalp vein catheter, catheter fracture, infants, 3D-CT reconstruction, body surface localization, ultrasound, intravascular foreign body, pediatric surgery, venous embolism, minimally invasive surgery, case report, BMC Pediatrics

A new explorative qualitative study published in BMC Pediatrics by Salome Keller of the Zurich University of Applied Science and colleagues at the Department of Chiropractic Medicine at University Hospital Balgrist and the University of Zurich has now documented, in parents’ own words, how attitudes toward chiropractic intervention evolve across the course of treatment for infants with suspected arthrogenic torticollis. The research team recruited families whose babies had been referred to chiropractic care with a suspected diagnosis of the condition and conducted semi-structured interviews at two points in time: a baseline round with twelve parents before or at the start of treatment, and a follow-up round with seven parents after they had experienced the therapy firsthand. The design allowed the investigators to compare expectations and fears before treatment with perceptions and judgments afterward, capturing a psychological trajectory that is rarely documented in this clinical population.

Methodologically, the study followed a deductive-inductive qualitative analysis based on Kuckartz’s approach, a structured framework for qualitative content analysis that combines theory-driven categories with themes emerging from the data themselves. All interviews were coded using MAXQDA 24, a widely used software platform for qualitative research, and the reporting was guided by the COREQ checklist, an international standard designed to improve the transparency and completeness of qualitative study reporting. From this analysis, four main themes crystallized: everyday life, perception of the infant’s health status, prior knowledge, and attitude toward chiropractic treatment. These themes formed an interpretive map of the parental experience, showing how the practical demands of caring for an affected infant, the parents’ reading of their child’s condition, whatever they knew beforehand about manual therapy, and their evolving stance toward the treatment all interacted to shape the overall journey.

The baseline interviews revealed a striking emotional landscape. Parents initially experienced considerable uncertainty and emotional strain, driven by two distinct sources. The first was simple unfamiliarity: chiropractic care for infants is not part of most parents’ medical vocabulary, and many did not know what the treatment would entail, how safe it was, or what evidence supported it. The second source was more visceral: watching a practitioner apply manual techniques to a tiny, fragile baby provoked anxiety that no amount of rational reassurance could entirely dispel. The researchers found that this ambivalence, a mixture of hope that the therapy would help and fear that it might somehow harm, was a defining feature of the pre-treatment mindset. Parents arrived at the clinic carrying questions they often felt hesitant to ask, and their first encounters with the treatment setting were colored by this underlying tension.

What happened next, according to the follow-up interviews, was a gradual transformation. As parents became familiar with the process, observing what the practitioner actually did, understanding the gentle nature of the techniques used on infants, and seeing how their baby responded during and after sessions, their emotional state shifted measurably. Confidence grew. Trust in the professionals deepened. Acceptance of the treatment, which had been tentative at best before the first session, solidified into genuine endorsement. Crucially, the researchers identified a powerful catalyst for this shift: observable improvement in the infant’s condition. When parents could see their child turning the head more freely, holding it more symmetrically, or feeding and sleeping more comfortably, their abstract anxieties about the therapy gave way to concrete, experience-based conviction that the intervention was working.

The study’s findings on the factors shaping parental attitudes carry practical weight for clinicians. Three elements stood out as decisive. Clear communication emerged as the foundation: parents who received thorough explanations of the diagnosis, the rationale for chiropractic treatment, and what each session would involve reported far less distress and far greater engagement than those left to guess. Observable health benefits formed the second pillar, providing the experiential evidence that no verbal reassurance could replace. Prior experience with therapeutic interventions for their infant constituted the third factor: families who had already navigated physiotherapy or other treatments for their child arrived with a framework for understanding a new therapy, which buffered the initial shock of the unfamiliar. Together, these factors suggest that the trajectory from skepticism to trust is not automatic but is actively constructed through information, demonstration, and results.

The clinical context makes these findings particularly significant. Arthrogenic torticollis, involving the upper cervical joints, is precisely the kind of diagnosis that prompts parents to seek specialized manual assessment, and chiropractic medicine in Switzerland, where the study was conducted, is an integrated, university-trained medical discipline rather than an alternative practice. At University Hospital Balgrist, chiropractic medicine operates within the hospital system, with practitioners trained to medical standards. Nevertheless, the researchers emphasize that the general public often does not distinguish between regulated, hospital-based chiropractic care and less formally grounded versions of the practice, which contributes to the initial wariness parents bring through the clinic door. The gap between the actual, regulated nature of the treatment and parental perceptions of it is exactly where communication interventions can do the most good.

The broader implications extend well beyond this single condition. The study offers a template for understanding how families engage with any unfamiliar treatment for infants, a situation that arises constantly in pediatrics, from osteopathy to novel physiotherapy protocols to emerging conservative orthopedic approaches. The central insight is that parental acceptance is dynamic, not fixed: it can be cultivated through structured communication and validated through visible outcomes. The authors highlight that supporting families through this psychological transition does more than improve satisfaction scores; it reduces stress during the infant’s care, and reduced parental stress is itself a meaningful clinical outcome, given how strongly caregiver anxiety can affect feeding, bonding, and the consistency with which families complete a treatment course.

The researchers are careful about the scope of their conclusions. As an explorative qualitative study with twelve baseline and seven follow-up participants, it cannot quantify how common each attitude pattern is, nor can it speak to the clinical efficacy of chiropractic treatment for arthrogenic torticollis itself, which was not the object of investigation. What it does establish, with methodological transparency, is the shape of the parental experience: an arc that begins in uncertainty and emotional strain, passes through familiarization and observation, and ends, for the families studied, in confidence and acceptance. The deductive-inductive coding framework and adherence to the COREQ checklist strengthen the trustworthiness of the thematic findings, and the two-timepoint design gives the study a longitudinal dimension that most qualitative work in this area lacks.

For parents facing a torticollis diagnosis, the study’s message is quietly reassuring: the fear and ambivalence they may feel before their infant’s first chiropractic session are common, documented, and, according to the families interviewed, likely to fade as understanding and visible progress replace the unknown. For clinicians, the message is more actionable. Every explanation offered before a session, every question answered patiently, and every improvement pointed out explicitly is not merely courtesy but an active ingredient in the therapy’s acceptance. In a field where the youngest patients cannot voice their own experience and their caregivers hold the decision-making power entirely, the psychology of the parent may be as important to a treatment’s success as the technique applied to the infant’s neck. This Swiss study makes that psychology visible, and in doing so, offers both families and practitioners a clearer map of the emotional terrain they must cross together.

Subject of Research: Parental attitudes toward chiropractic treatment of infants with arthrogenic torticollis

Article Title: Parental attitude towards chiropractic intervention before and after treatment in infants with an arthrogenic torticollis: an explorative qualitative study

Article References: Keller, S., Paravicini, I., Wirth, B., Schweinhardt, P., & Langenfeld, A. (2026). Parental attitude towards chiropractic intervention before and after treatment in infants with an arthrogenic torticollis: an explorative qualitative study. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07760-z

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07760-z

Keywords: arthrogenic torticollis, chiropractic care, parental attitude, infants, manual therapy, parental stress, healthcare communication, pediatrics, qualitative research, congenital muscular torticollis, cervical spine, physiotherapy

The research team, based at the asthma and allergy clinic of Shahid Beheshti Hospital and affiliated with Kashan University of Medical Sciences, combed through electronic medical files from January 2005 to December 2021. Their inclusion criteria were strict: infants between six and twenty-four months of age with a diagnosis of atopic dermatitis and a completed skin prick test panel. Babies whose medications could not be safely paused, those with severe skin disease other than eczema, and any infant with a history of anaphylaxis to food were excluded, as were patients with incomplete records. After applying these filters, ninety-eight infants made it into the final analysis, a modest but carefully characterized cohort that received ethics approval and parental informed consent for every case.

The skin prick test itself deserves a technical word, because its simplicity belies the immunology it captures. Clinicians placed standardized extracts of eight common food allergens—milk, egg, tree nuts, soybean, wheat, seafood, rice, and peanut—onto a small scratch on the palm side of the infant’s forearm. Antihistamines and systemic steroids were halted a full week beforehand to avoid blunting the response. After fifteen to twenty minutes, the site was inspected: a wheal greater than three millimeters, accompanied by erythema exceeding eight millimeters, counted as positive. The researchers then graded reactions by size, treating wheals of three to five millimeters as mild, five to ten as moderate, and anything beyond ten as severe. The test works by detecting allergen-specific immunoglobulin E, or IgE, antibodies parked on mast cells in the skin; when the extract cross-links those antibodies, the cells dump histamine and other inflammatory mediators, producing the visible swelling within minutes.

The headline result was unambiguous. Egg allergy appeared in 64.3 percent of the infants, cow’s milk in 49 percent, tree nuts in 35.7 percent, soy in 20.4 percent, and wheat in 12.2 percent. Girls made up the majority of the cohort at 55.1 percent, and most babies—66.3 percent—had mild disease, with 24.5 percent moderate and only 9.2 percent severe. The average age at which eczema first appeared was just under six months, at 5.72 months, underscoring how early in life the disease and its dietary entanglements begin. Feeding history in the first half-year was also recorded: 63.3 percent of infants were exclusively breastfed, 13.3 percent received only formula, and the rest a combination of the two.

Two statistically significant patterns emerged from the cross-tabulations. First, egg allergy was markedly more common in girls than in boys, affecting 74.1 percent of female infants versus 52.3 percent of males, a difference the authors reported as significant at p equals 0.025. Second, cow’s milk allergy clustered in early-onset disease: 56.06 percent of infants whose symptoms began before six months of age were sensitized to milk, compared with 34.3 percent of those whose eczema appeared later, significant at p equals 0.044. Wheat sensitization showed a striking fivefold elevation in the early-onset group, 16.6 percent versus 3.1 percent, but the small numbers in each subgroup kept this from reaching statistical significance. Notably, the type of allergen bore no relationship to how the infant was fed in the first six months, nor to the severity of the eczema itself.

Severity did, however, track tightly with timing. Infants with severe atopic dermatitis had developed symptoms at an average age of just 2.78 months, compared with 7.17 months in the moderate group and 5.60 months in the mild group, a difference significant at p equals 0.014. This aligns with a broader clinical observation that the earliest and most aggressive presentations of eczema often mark children destined for the so-called atopic march, the progression from skin disease to food allergy, allergic rhinitis, and asthma. Immunologically, atopic dermatitis is driven by a skewed T helper 2 response, with interleukins IL-4, IL-5, and IL-13 ramping up IgE production and activating eosinophils and mast cells. When food antigens enter this primed environment, B lymphocytes pump out allergen-specific IgE, which arms mast cells and basophils via their Fc receptors; re-exposure then triggers the full allergic cascade.

The Kashan results sit within a patchwork of international findings that highlight how geography and diet shape allergen profiles. A Chinese study of nearly 1,700 children under two identified egg, shrimp, and fish as leading triggers, while Iranian work in Mashhad found egg white, egg yolk, and cow’s milk at the top of the list. In Bushehr, southern Iran, peanuts, walnuts, and soybeans dominated, and Czech researchers reported nuts, milk, and peanuts as the chief offenders among older patients. The authors of the new study attribute this variability to differences in dietary habits, culture, ethnicity, and age of the studied populations, along with a straightforward epidemiological principle: the more a population consumes a given food, the more likely its members are to become sensitized to it. Cow’s milk and egg, staples of infant diets nearly everywhere, recur as the leading allergens across most regions, including prior Iranian surveys.

Perhaps the most consequential implication of the study is what it says about feeding practices. The researchers found no association between breastfeeding, formula feeding, or mixed feeding and either allergen sensitization or disease severity, a result consistent with systematic reviews that have failed to demonstrate a clear protective or predisposing effect of exclusive breastfeeding on atopic outcomes. This echoes earlier Iranian work showing that breastfeeding patterns and the timing of complementary foods did not influence eczema incidence or severity. The practical message is twofold: infant feeding choices alone cannot explain allergic outcomes without accounting for genetic susceptibility and immune mechanisms, and clinicians should resist reflexively prescribing long lists of foods to eliminate from both mother’s and baby’s diets, a practice the authors note can produce what they describe as double starvation and injury. Precise identification of the offending allergen, followed by targeted avoidance, is the strategy that actually improves quality of life.

The study is candid about its limits. Its retrospective design depended on medical records rather than prospective enrollment, more than forty-five cases were dropped for missing data, and the skin prick test, while valuable, detects sensitization rather than clinically confirmed allergy. Without confirmatory serum-specific IgE measurements or oral food challenges, the true prevalence of food allergy may have been overestimated. Moreover, atopic dermatitis comes in two immunological flavors: the extrinsic, IgE-mediated form that prick testing captures well, and the intrinsic, non-IgE-mediated form, in which patients show classic eczema despite normal IgE levels and negative tests. The Kashan findings therefore largely reflect sensitization patterns in extrinsic disease and may underestimate food-related triggers in intrinsic cases. The authors call for prospective, multicenter studies with larger samples, standardized severity scoring, and confirmatory diagnostics such as oral food challenges to sharpen the picture.

Even with those caveats, the sixteen-year dataset delivers a clear clinical takeaway. Infants with eczema in this Iranian population were most frequently sensitized to egg, cow’s milk, and nuts; egg sensitization skewed female, milk sensitization skewed toward early-onset disease, and the earliest symptom onset predicted the most severe eczema. Because food sensitivity in many patients begins before six months of age, the authors recommend that highly allergenic items such as egg yolk and wheat not be introduced into infant diets before that age. In an era when allergic diseases of every type are rising worldwide, region-specific maps of allergen frequency like this one are becoming essential instruments for pediatricians navigating the fine line between protecting vulnerable infants and depriving them of nutrition they can safely tolerate.

Subject of Research: Food allergen sensitization patterns in infants with atopic dermatitis assessed by skin prick testing

Article Title: Assessment of Common Food Allergens in Infants With Atopic Dermatitis in Kashan From 2005 to 2021

Article References: Madani, S. R., Salehi, M., Arani, M. H., Shaterian, Z., Heidari, M. M., & Azadchehr, M. J. (2026). Assessment of Common Food Allergens in Infants With Atopic Dermatitis in Kashan From 2005 to 2021. Immunity, Inflammation and Disease, 14(10), Article e70544. https://doi.org/10.1002/iid3.70544

Image Credits: AI Generated

DOI: 10.1002/iid3.70544

Keywords: atopic dermatitis, food allergy, infants, skin prick test, egg allergy, cow's milk allergy, IgE, eczema, Iran, pediatric allergy, breastfeeding, atopic march

The research, published in BMC Pediatrics, comes from a team at Shanghai Children’s Medical Center led by Xinyi Xu and colleagues, including corresponding author Tingliang Liu. The investigators combed through fifteen years of clinical records, spanning 2009 to 2024, at their tertiary children’s hospital in China. From that archive they identified 101 children diagnosed with tachycardia-induced cardiomyopathy, 58 of them boys. The median age at diagnosis was strikingly young: just 1.4 years, with the middle half of patients falling between roughly four months and seven years old. That age profile alone tells an important story, because it means the condition frequently strikes infants and toddlers, patients too young to describe palpitations or chest discomfort and whose symptoms are easily mistaken for ordinary childhood illness.

The central finding concerns the arrhythmias that set the disease in motion. Focal atrial tachycardia, an abnormal rhythm originating from a discrete spot in the heart’s upper chambers, accounted for 55.4 percent of cases, making it by far the most common culprit. Other rhythm disturbances in the pediatric TIC spectrum include atrial flutter, atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia, chaotic atrial tachycardia, junctional ectopic tachycardia, and ventricular tachycardia. Each of these rhythms forces the ventricles, the heart’s main pumping chambers, to beat far faster than they were designed to. When that pace persists, the heart muscle exhausts itself in a way that cardiologists compare to a sprinter forced to run a marathon: the chambers dilate, the pumping fraction measured by echocardiography falls, and the child can slide into heart failure.

What makes TIC clinically fascinating, and diagnostically treacherous, is that the muscle damage is potentially reversible. Unlike many cardiomyopathies, which reflect intrinsic disease of the heart muscle itself, TIC is a secondary phenomenon: remove or control the arrhythmia, and the pump often recovers. The Shanghai team’s data quantify just how often that recovery happens. At a median follow-up of 34 months, ranging from 14 to 67 months, the tachyarrhythmia driving the disease had resolved spontaneously in 46 of the 101 patients, or 45.5 percent. In other words, in nearly half the cohort, the abnormal rhythm simply stopped on its own over time, and with it the stimulus that had been wearing the heart down.

The study goes beyond describing outcomes by identifying which children recover fastest. Using statistical modeling, the researchers pinpointed three independent predictors of recovery of the left ventricular ejection fraction, the standard measure of pumping strength. The first was age at TIC onset: each additional year of age at diagnosis was associated with a hazard ratio of 0.912 for ejection fraction recovery, with a 95 percent confidence interval of 0.863 to 0.964 and a p-value of 0.001. In practical terms, older children recovered more slowly than infants. The second predictor was the nature of the rhythm itself: incessant tachycardia, meaning an arrhythmia present nearly continuously rather than in intermittent bursts, carried a hazard ratio of 0.480, indicating markedly slower recovery of pumping function. The third was the baseline degree of left ventricular dilation, measured as the end-diastolic dimension Z-score, a statistical correction that accounts for a child’s body size. For every one standard deviation increase in that Z-score, the hazard ratio for recovery was 0.828, meaning a more stretched-out ventricle at diagnosis predicted a slower climb back to normal function.

These predictors give clinicians a practical risk stratification tool. A toddler whose heart races around the clock and whose left ventricle is already significantly dilated at presentation is the patient who will need the most aggressive rhythm control and the closest monitoring. Conversely, an infant with a milder, intermittent arrhythmia and a ventricle that is only mildly enlarged has a good prognosis even before treatment begins. The findings also reinforce a principle that pediatric cardiologists have long suspected: the duration and burden of the tachycardia, not merely its type, determine how much the heart suffers and how long it takes to heal.

Infants, however, occupy a paradoxical position in the study’s results. On one hand, children aged one year or younger had dramatically better odds of spontaneous resolution of their arrhythmia, with an odds ratio of 8.309 compared with older children. The immature heart’s conduction system, for reasons the study does not fully resolve, appears more likely to simply outgrow certain abnormal rhythms. On the other hand, when infants did require catheter ablation, the procedure that threads catheters into the heart to destroy the tissue generating the abnormal rhythm, their complication rates were sobering. Ablation-related adverse events occurred in 66.7 percent of children one year old or younger, two out of three patients in that small subgroup, compared with just 8.7 percent of children older than one year, four out of 46. The difference was statistically significant, with a p-value of 0.04.

That trade-off sits at the heart of the clinical dilemma the study illuminates. Ablation in a tiny infant is technically demanding: the heart is the size of a walnut, the arrhythmia focus may be millimeters across, and the catheters and mapping systems were largely engineered for adult anatomy. Yet waiting for spontaneous resolution is not always safe when the heart is failing. The study’s numbers suggest a reasoned approach: in infants, particularly those whose arrhythmias are intermittent and whose ventricles are not severely dilated, a strategy of medical rhythm control and watchful waiting may be justified by the high likelihood of spontaneous resolution. In older children, where spontaneous resolution is less common and ablation is far safer, earlier catheter-based intervention becomes more attractive, especially when the arrhythmia is incessant and the clock is ticking on ventricular recovery.

The broader significance of the study lies in its scale and duration. Fifteen years of single-center experience with 101 patients is a substantial dataset for a condition that most pediatric centers encounter only a handful of times per decade. Because the analysis is retrospective, it inherits the limitations of that design: treatment decisions were made by individual clinicians rather than a protocol, and the findings describe associations rather than the effects of randomized interventions. Still, the consistency of the three prognostic factors, age, arrhythmia persistence, and ventricular dilation, across the statistical models gives the results weight, and the cohort size lends the estimates a precision that smaller case series cannot match.

For families, the headline message is ultimately an encouraging one. Most children in the study recovered fully once their heart rhythm was brought under control, whether through medication, ablation, or the arrhythmia’s own spontaneous disappearance. Tachycardia-induced cardiomyopathy, frightening as it sounds when a child’s ejection fraction plummets, is in most cases a temporary state rather than a permanent sentence. The challenge, as the Shanghai data make clear, is matching the right treatment to the right child at the right time: protecting the hearts of infants whose rhythms may resolve on their own, while moving decisively in older children whose incessant arrhythmias and dilated ventricles signal a longer, harder road to recovery. With this fifteen-year map in hand, pediatric cardiologists now have firmer ground on which to make those decisions.

Subject of Research: Clinical management and prognosis of tachycardia-induced cardiomyopathy in children

Article Title: Clinical management and prognosis of tachycardia-induced cardiomyopathy in children: a retrospective cohort study with 15-year single-center experience

Article References: Xu, X., Feng, W., Wang, K., Ji, W., Guo, Y., Wu, J., Chen, Y., Zhu, D., Li, F., & Liu, T. (2026). Clinical management and prognosis of tachycardia-induced cardiomyopathy in children: a retrospective cohort study with 15-year single-center experience. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07712-7

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07712-7

Keywords: tachycardia-induced cardiomyopathy, pediatric cardiology, arrhythmia, focal atrial tachycardia, catheter ablation, left ventricular ejection fraction, heart failure in children, spontaneous resolution, infants, retrospective cohort study, echocardiography, prognosis

The original study, published on 18 August 2026, set out to answer a deceptively simple question: when a trained examiner palpates and assesses the upper cervical spine of an infant, does that clinical judgment correspond to what is visible on radiological digital images of the same region? The upper cervical spine, comprising the atlas and axis vertebrae at the top of the spinal column, is a technically demanding area to evaluate in babies. Infants cannot report symptoms, the anatomy is small and largely cartilaginous, and positional asymmetries of the head and neck, often presenting as torticollis, can arise from many different underlying causes. Establishing whether hands-on assessment tracks with imaging findings is therefore a methodologically meaningful question, and one with direct implications for how clinicians decide when imaging is warranted.

In their letter, Tahir and colleagues acknowledged the methodological quality of the Swiss work and expressed general agreement with the authors’ interpretation of the findings. Their critique, however, focused on two distinct issues. The first concerned the use of radiological digital pictures of the upper cervical spine in infants presenting with torticollis. The second concerned the use of spinal mobilization as a treatment approach for the same condition. Crucially, the letter framed both objections in the context of congenital muscular torticollis, a specific diagnosis in which shortening or fibrosis of the sternocleidomastoid muscle causes the head to tilt and rotate. That framing, the Swiss authors argue, is where the critique loses its footing.

In their reply, published on 9 September 2026, Jan Peter, Miklos Csato, Inga Paravicini, Martina Wehrli, Petra Schweinhardt and Anke Langenfeld point out a fundamental mismatch between the critique and their study population. The infants enrolled in the cross-sectional study had been referred for chiropractic assessment and treatment only after undergoing evaluation for congenital muscular torticollis by the referring pediatrician or chiropractor. None of the infants had actually received a diagnosis of congenital muscular torticollis. In other words, the study examined a group of babies whose head and neck posture problems remained unexplained after the most common muscular cause had been ruled out, a population that is clinically distinct from the one the letter’s cited guidelines address.

This distinction matters because torticollis is not a single disease but a descriptive sign. Congenital muscular torticollis is the most frequent cause in infancy, but positional plagiocephaly, ocular imbalance, skeletal anomalies, and neurological conditions can all produce a similar tilted head posture. Guidelines recommending one management pathway or another are typically written for a specific diagnosis, and the Swiss authors note that the guidelines cited in the critical letter refer specifically to congenital muscular torticollis, not to other forms of torticollis. Applying those recommendations to a cohort deliberately composed of infants without that diagnosis, they contend, misreads what the study was designed to show.

The second point of contention, spinal mobilization in infants, touches on one of the most sensitive debates in pediatric musculoskeletal care. An international evidence-based position statement for physiotherapists, published in 2024 by Gross, Olson, Pool and colleagues in the Journal of Manual and Manipulative Therapy, advises against any form of spinal mobilization or manipulation in infants, irrespective of diagnosis. The Swiss authors state that they are very much aware of this position statement and do not dispute its content. Instead, they draw attention to its evidentiary basis: the statement, they note, rests on the limited availability of high-quality evidence, meaning that no firm conclusion can currently be reached about the effectiveness or safety of manual treatments in this age group.

The authors are equally emphatic that their own study cannot fill that gap. The objective of the cross-sectional study, they stress, was not to evaluate treatment effectiveness or to compare therapeutic approaches. Accordingly, they write, the findings should not be interpreted as evidence supporting or rejecting the appropriateness or effectiveness of any particular intervention. This is a point of scientific logic as much as of clinical policy: a study that measures agreement between two diagnostic assessments, in this case examiner judgment and radiological imaging, says nothing about whether treating the identified findings changes outcomes for the child. Conflating diagnostic correlation studies with treatment trials is a common source of misinterpretation in the literature, and the reply serves as a pointed reminder of the difference.

At the same time, the exchange highlights a genuine and unresolved tension in the field. If high-quality evidence on manual therapy in infants is scarce, then both the clinicians who use these techniques and the bodies that advise against them are operating in an evidentiary vacuum. The Swiss authors close their reply by fully agreeing that high-quality evidence on both the effectiveness and the safety of manual treatments in infants, including spinal mobilization and manipulation, is urgently needed. That concession is notable: rather than dismissing the critique, they accept its most important implication while defending the narrower claims of their own research. The letter, they conclude, was critical yet constructive, and they welcome it as such.

For readers outside the specialty, the dispute is a case study in how carefully study populations must be defined before research findings can be generalized. A cohort of infants referred for chiropractic assessment after congenital muscular torticollis was excluded is not a cohort of infants with congenital muscular torticollis, and conclusions drawn from one cannot be transplanted to the other. Similarly, a measurement that is reliable, meaning that repeated assessments produce consistent results, does not automatically constitute a reliable diagnosis, a point captured in the very title of the critical letter. Reliability speaks to consistency; diagnostic validity speaks to whether the measurement identifies a true underlying condition. The two concepts are related but distinct, and much of the friction in this exchange flows from the gap between them.

The reply, authored by clinicians and researchers from the Department of Chiropractic Medicine and the Department of Radiology at Balgrist University Hospital and the University of Zurich, was received on 24 August 2026, revised on 28 August, accepted on 2 September, and published as an open-access Matters Arising contribution. Corresponding author Anke Langenfeld and Petra Schweinhardt drafted the response, with the remaining authors critically reviewing and approving it. The authors declare no competing interests. Whether the exchange will stimulate the large, rigorous trials that both sides agree are lacking remains to be seen, but the episode demonstrates how the peer-reviewed correspondence column continues to function as a venue for sharpening the questions that matter, particularly in a field where the patients are too young to speak for themselves and the stakes of getting the evidence right could not be higher.

Subject of Research: Diagnostic correlation between examiner judgment and radiographic imaging of the upper cervical spine in infants with torticollis

Article Title: Reply to: “A reliable measurement is not the same as a reliable diagnosis” by Nawaz Tahir et al.

Article References: Peter, J., Csato, M., Paravicini, I., Wehrli, M., Schweinhardt, P., & Langenfeld, A. (2026). Reply to: “A reliable measurement is not the same as a reliable diagnosis” by Nawaz Tahir et al.. Pediatric Radiology. https://doi.org/10.1007/s00247-026-06783-z

Image Credits: AI Generated

DOI: 10.1007/s00247-026-06783-z

Keywords: pediatric radiology, torticollis, congenital muscular torticollis, upper cervical spine, chiropractic medicine, spinal mobilization, radiography, diagnostic reliability, infants, manual therapy, position statement, Balgrist University Hospital

Positional plagiocephaly develops when sustained external pressure is placed on one area of a baby’s soft, still-forming skull. Because an infant’s cranial bones are pliable in the first months of life, repeated pressure on the same spot, most often the back of the head, can produce a visible asymmetrical flattening, usually involving the occipital bone at the rear of the cranium. That flattening can trigger compensatory shifts in anterior structures, including the orbits around the eyes and the middle ear, which is one reason pediatricians take the condition seriously even though it is often considered primarily cosmetic. The condition typically emerges in the first few months of life, when babies spend long stretches lying on their backs.

The prevalence of positional plagiocephaly rose dramatically after pediatricians began recommending that babies sleep on their backs, a public health campaign credited with saving lives by reducing the risk of sudden infant death syndrome. According to the researchers, the Back to Sleep campaign has been associated with a 600 percent increase in plagiocephaly prevalence and a corresponding surge in referrals for evaluation and treatment. One clinical trial cited in the abstract found plagiocephaly in 205 of 440 infants between 7 and 12 weeks of age, an incidence of roughly 46.6 percent. The researchers are careful to note that back sleeping remains essential for infant safety; the challenge is managing the skull flattening that can accompany it without compromising safe sleep practices.

Current management of positional plagiocephaly typically consists of conservative measures. Families are usually advised to try repositioning strategies, such as encouraging more tummy time while the baby is awake and supervised, and shifting the orientation of the infant’s head during sleep and feeding. Physical therapy may be recommended when muscle tightness in the neck, a common contributor to head turning preferences, appears to be driving the asymmetry. For infants with persistent or more severe deformity, helmet therapy, in which a custom-molded orthotic device is worn for many hours a day over months, remains an option for selected patients. Yet many families find helmets burdensome, expensive, or emotionally difficult, and repositioning alone does not always resolve the flattening.

That gap in options is what motivated the research team behind the OPT-IN trial, a two-arm, randomized cross-over clinical trial comparing osteopathic manipulative treatment with the standard of care of repositioning. Kimberly Wolf, DO, FAAP, FACOP, FAAPO, NABBLM-C, one of the study authors, said that families of infants with plagiocephaly often want treatment options that are gentle and non-invasive, and that the study demonstrates osteopathic manipulative treatment is safe, well accepted by families, and provides additional benefits for the baby’s health. She added that a flat head is a common reason parents bring their infants to the pediatrician in the first few months of life, yet until now families have had strikingly few choices for treatment, and the team wanted to find an option that works with the baby’s own body to improve head shape and address the root causes behind the flattening.

The interim analysis focused specifically on two questions: how safe and how feasible osteopathic manipulative treatment is for infants enrolled between birth and four months of age. Safety was assessed by tabulating and describing adverse events as reported by both families and the medical team. Feasibility was measured through adherence to the treatment schedule and through family satisfaction, which was captured in two ways: a feedback survey sent to caregivers upon completion of the eight-week intervention, and focus groups conducted with caregivers after the intervention ended. Importantly, all family satisfaction data were collected and analyzed by consultants unknown to the families, who de-identified the data before sharing results with the research team, a design choice intended to reduce bias in the reporting of subjective outcomes.

The preliminary results were striking in their consistency. Among the 67 families who completed the study, adherence reached 100 percent compliance across a total of ten visits per participant, comprising eight osteopathic manipulative treatment visits and two measurement visits. No serious adverse events occurred, leading the researchers to conclude that the treatment is safe and well tolerated by infants. The few concurrent symptoms that were reported, such as fussiness, were described as mild, not bothersome to the family, and quickly resolved. In a field where even minor adverse events can derail a pediatric intervention, a perfect completion rate across hundreds of visits is a notable feasibility finding in its own right.

Beyond the primary goal of improving head shape, parents whose infants completed the treatment visits reported a range of secondary benefits, including improvements in feeding, fussiness, reflux, and sleep. Parents also highlighted how important the therapy was as an alternative to helmets, which many families had been offered as a treatment option. In survey feedback summarized by the researchers, one parent described the experience as gentle, effective, and awesome. The survey results, drawn from 44 respondents, were described as very positive, showing that families viewed the hands-on approach as both a safe and a feasible option for treating plagiocephaly. Study author Kaur Sirjen is scheduled to present the research from 12 to 12:30 PM Pacific time on Sunday, October 4, and Dr. Wolf was among the highlighted abstract authors giving a brief presentation during a conference soundbite session.

The researchers conclude that osteopathic manipulative treatment should be considered for families seeking a non-invasive treatment option for managing positional plagiocephaly. Still, the usual scientific caveats apply. These are interim results from a safety and feasibility analysis, not the trial’s final efficacy verdict; the randomized cross-over design of the full OPT-IN trial is intended to compare the therapy directly against repositioning on head shape outcomes, and those comparative data will determine whether the enthusiasm generated by family satisfaction translates into measurable cranial improvement. The findings have been presented at a scientific conference rather than published in a peer-reviewed journal, meaning they have not yet undergone formal external review. Even so, for a condition affecting nearly half of infants in some cohorts, and for parents weighing months of helmet therapy against watchful waiting, the prospect of a gentle, hands-on treatment with a clean safety record and near-perfect family adherence is a development worth watching closely as the trial progresses.

Subject of Research: Safety and feasibility of osteopathic manipulative treatment for infant positional plagiocephaly

Article Title: Hands-on treatment studied as option in treating baby flat head syndrome

Article References: Hands-on treatment studied as option in treating baby flat head syndrome. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: positional plagiocephaly, osteopathic manipulative treatment, infants, flat head syndrome, pediatrics, helmet therapy, Back to Sleep campaign, randomized clinical trial, American Academy of Pediatrics, tummy time, safety, family satisfaction

The study, published in the Journal of Activity, Sedentary and Sleep Behaviors, tackled two questions at once. First, how many days and hours of parent reporting are needed before the app’s estimates of physical activity, sedentary behavior, and sleep become statistically reliable? Second, do the app’s classifications actually correspond to what a body-worn accelerometer records during the same moments of a child’s day? Both questions matter because the first years of life are a period of explosive development in which movement habits begin to form, and health guidelines from the World Health Organization already prescribe targets for sleep, sitting, and activity in children under five, even though the tools for measuring compliance remain crude.

The researchers drew on the My Little Moves cohort study, recruiting families through daycare centers, youth health services, and community organizations across the Netherlands. In total, 324 children, averaging about 22 months of age, contributed at least two days of app data for the reliability analysis. A smaller subgroup of 75 children, averaging about 20 months, also wore two Axivity AX3 accelerometers, one on the left wrist and one on the right hip, for eight consecutive days. The devices are tiny, weighing just 11 grams, and captured raw triaxial acceleration at 50 Hz around the clock, except during bathing. Parents were asked to log their child’s activities in the app for seven consecutive days, from midnight to midnight.

The app itself works like a digital time-use diary. Parents select from eleven activity categories, including personal care, eating and drinking, active transport, passive transport, playing, screen use, sitting or lying calmly, and sleeping, and record the start and stop time of each activity in five-minute increments. Follow-up questions probe the intensity of play, the child’s posture, and the context, such as location. Crucially, the app adapts its content to the child’s developmental stage: parents enter the child’s age and motor milestones, such as rolling over, sitting, crawling, or walking, and the activity categories and questions adjust accordingly. Reporting takes parents roughly 10 to 30 minutes per day, a burden the researchers acknowledge is not trivial.

To determine the minimum reporting time, the team applied the Spearman-Brown prophecy formula to single-day intraclass correlations, testing every combination of daily reporting hours from 12 to 24 and monitoring periods from two to seven days. The results were specific. Reliable estimates of sleep required at least two days of 20 reported hours. Physical activity required two days of 23 hours. Sedentary behavior proved the most demanding, needing four days of 17 hours. For the overall composition of the 24-hour day, in which the three behaviors are analyzed together as mutually exclusive shares of time, two days of 23 hours sufficed. Notably, the study also found significant differences between weekdays and weekend days for most behaviors, underscoring the importance of capturing both in any monitoring window.

The validity analysis took an unusual route, because there is no gold standard for measuring movement behaviors in infants and toddlers, and no validated cut-points exist for translating raw acceleration into activity classes across the full 0-to-4 age range. Instead, the researchers tested hypotheses about how accelerometer-derived acceleration should behave if the app’s classifications were meaningful. The central prediction: acceleration should be lowest during app-reported sleep, intermediate during sedentary behavior, and highest during physical activity. Using the open-source GGIR software, they computed two metrics, the Euclidean norm minus one (ENMO) and the mean amplitude deviation (MAD), for both hip and wrist placements, and matched every five-second epoch of acceleration to the parent-reported activity in progress at that moment.

The main hypothesis held up cleanly. Across both sensor placements and both metrics, acceleration differed significantly among the three behaviors in exactly the predicted order, with p-values below 0.001. The explained variance was moderate to substantial, reaching an R-squared of 0.37 for wrist-worn MAD, suggesting that the app’s broad behavioral categories map onto genuinely different patterns of body movement. The researchers then pushed further, formulating 55 sub-hypotheses about expected similarities and differences in acceleration across the app’s finer activity categories. Consistent support emerged for 21 of them. Active play and active transport reliably produced higher acceleration than sitting, personal care, eating, and passive screen use, while sleep produced lower acceleration than nearly everything else.

But the finer-grained comparisons also exposed instructive failures. Passive transport, meaning a child being pushed in a stroller or carried in a car seat, generated significantly higher acceleration than other sedentary categories and was indistinguishable from genuine physical activity. The reason is a known blind spot of accelerometry in early childhood: the sensor records the motion of whoever is moving the child, not just the child’s own movement. The finding, the authors argue, is a clear signal that current accelerometer processing methods need rethinking for the youngest age groups. Screen use posed its own puzzle: passive screen use showed the lowest acceleration of all sedentary activities, echoing laboratory findings in older children, while active screen use, such as dancing in front of a television, was reported only three times in the entire dataset, too rarely to draw conclusions.

The study has honest limitations. The comparison sample of 75 children falls short of the roughly 100 participants recommended for measurement-instrument validation studies, and most participating parents were highly educated women, which may limit generalizability. Parents reported activities in blocks of about 30 minutes, making the app insensitive to rapid posture changes such as brief episodes of tummy time, an issue for monitoring infant-specific recommendations. Excluding the categories for unknown activities and time with other caregivers, which accounted for 3.4 percent of reports, may have introduced systematic bias, particularly since many young children spend long hours in daycare outside parental sight. Attrition was also notable: 22 percent of parents who started never logged any activities at all.

Even so, the practical takeaway is concrete. Two full days of app reporting, of at least 23 hours each, are enough to obtain a reliable picture of how a child under four divides the day between moving, sitting, and sleeping, and the app’s categories behave in physiologically plausible ways when checked against objective motion data. The authors recommend combining the app with accelerometry in future research, since the two tools capture complementary information: sensors quantify movement continuously, while the app supplies the context, the type of activity, and the setting that sensors cannot see. They also call for data-driven machine learning models to translate raw acceleration into behavior estimates for infants and toddlers, including daytime naps, and for clearer scientific definitions of what physical activity even means in children who cannot yet walk. For a field long forced to extrapolate from tools built for school-aged children, the message is that measuring the earliest years properly is finally within reach, one parent-reported five-minute block at a time.

Subject of Research: Reliability and validity of a parent-report mobile app for assessing 24-hour movement behaviors in children aged 0 to 4 years

Article Title: Assessing 24-h movement behaviors in early childhood (0–4 years): Reliability of the My Little Moves app and comparison with accelerometry

Article References: Lettink, A., Arts, J., Gubbels, J. S., Altenburg, T. M., & Chinapaw, M. J. M. (2025). Assessing 24-h movement behaviors in early childhood (0–4 years): Reliability of the My Little Moves app and comparison with accelerometry. Journal of Activity, Sedentary and Sleep Behaviors, 4(1), Article 5. https://doi.org/10.1186/s44167-025-00075-x

Image Credits: AI Generated

DOI: 10.1186/s44167-025-00075-x

Keywords: physical activity, sedentary behavior, sleep, infants, toddlers, preschoolers, accelerometry, mobile app, time-use diary, measurement validity, 24-hour movement behaviors, child health

Congenital hypogonadotropic hypogonadism is a condition in which the hypothalamic-pituitary-gonadal axis, the hormonal circuit that governs sexual development, fails to activate properly. In affected children, the hypothalamus does not release adequate gonadotropin-releasing hormone, or the pituitary gland fails to respond to it, leaving the gonads without the signals they need to mature. The result is gonadal insufficiency and abnormalities of the external genitalia, including cryptorchidism and micropenis, which are often the first visible clues. Because the disorder is rare and its signs can be subtle in infancy, diagnosis is frequently delayed, sometimes until puberty fails to arrive, by which point critical windows for treatment and bone and reproductive development may have been compromised.

The challenge for pediatricians is that there is a natural period when diagnosis is both possible and difficult. Shortly after birth, male infants experience what researchers call mini-puberty, a transient surge of activity along the hypothalamic-pituitary-gonadal axis that occurs roughly from birth to about six months of age. During this window, luteinizing hormone, follicle-stimulating hormone, testosterone, and other sex hormones normally rise to levels approaching those of puberty before settling back to low childhood values. Mini-puberty offers clinicians a rare biochemical opportunity to interrogate the axis in a baby. But in children between six months and three years, the axis goes quiet, and the usual hormone signals fall to levels that are hard to interpret, making the diagnostic window narrow and the interpretation tricky.

To explore whether additional markers could sharpen early diagnosis, the research team led by Dongxia Fu, Xue Wu, Huizhen Wang, Yongxing Chen, and corresponding author Haiyan Wei conducted a case-control study of male infants and toddlers with congenital hypogonadotropic hypogonadism who were hospitalized between January 1, 2018, and December 31, 2019. They enrolled 25 affected boys and divided them into two age groups: those aged six months or younger, capturing the mini-puberty window, and those between six months and three years, when the axis is normally quiescent. For comparison, they recruited healthy controls matched at a ratio of four controls per case, allowing robust statistical comparison across physical examination findings, biochemical indices, sex hormone levels, anti-Müllerian hormone, and inhibin B.

The analytical strategy centered on comparing these measurements between the affected and healthy groups and then testing which markers best discriminated the two. The researchers used receiver operating characteristic, or ROC, analysis, a standard statistical technique that evaluates how well a test separates diseased from healthy individuals. The area under the ROC curve, or AUC, ranges from 0.5, meaning no better than chance, to 1.0, meaning perfect discrimination. Values above 0.9 are generally considered excellent. When the team applied this framework, three molecules stood out as factors associated with CHH: anti-Müllerian hormone, inhibin B, and estradiol.

The headline result concerns estradiol. In the group of infants aged six months or younger, estradiol achieved an area under the curve of 0.951, with a diagnostic cutoff of 9.79 picograms per milliliter. In the older group of children between six months and three years, the area under the curve was 0.939, with a cutoff of 5.55 picograms per milliliter. In both age bands, estradiol showed the strongest diagnostic efficacy of any marker tested. Notably, the study found no statistically significant differences in diagnostic efficacy among luteinizing hormone, follicle-stimulating hormone, estradiol, inhibin B, and anti-Müllerian hormone when compared directly, suggesting that estradiol performs at least as well as the established gonadotropins and Sertoli cell markers rather than replacing them outright.

Why would estradiol, an estrogen, carry diagnostic information about underactive testes in boys? The biology is more intertwined than the name suggests. In males, a substantial fraction of circulating estradiol is produced through aromatization, the enzymatic conversion of testosterone into estradiol in peripheral tissues, and the testes themselves contribute directly. When the hypothalamic-pituitary-gonadal axis fails to fire during mini-puberty, testosterone production stays low, and with it the substrate for estradiol production. Low estradiol in a baby boy during mini-puberty is therefore a downstream echo of the same upstream failure that suppresses luteinizing hormone and follicle-stimulating hormone signaling. In the older toddler group, where baseline hormone levels are naturally low in all children, the estradiol cutoff shifts downward to 5.55 picograms per milliliter, reflecting the quieter hormonal milieu but retaining strong discriminatory power.

The study’s other two standout markers, anti-Müllerian hormone and inhibin B, are both products of Sertoli cells, the nurse cells of the seminiferous tubules that support developing germ cells. Anti-Müllerian hormone is responsible for regressing the Müllerian ducts during male embryonic development and remains a sensitive readout of Sertoli cell activity throughout childhood. Inhibin B, which feeds back on the pituitary to regulate follicle-stimulating hormone, likewise reflects functional testicular tissue. In congenital hypogonadotropic hypogonadism, the gonads are structurally capable but chronically understimulated, and both markers register the deficit. The authors found that the combination of low anti-Müllerian hormone and low inhibin B, interpreted alongside the estradiol cutoffs of 9.79 picograms per milliliter for mini-puberty and 5.55 picograms per milliliter for the six-month to three-year range, significantly improved early detection compared with any single measure alone.

The practical implications reach beyond the laboratory. Distinguishing congenital hypogonadotropic hypogonadism from other causes of gonadal dysfunction in infancy, such as androgen insensitivity syndrome or 5-alpha-reductase deficiency, both of which can present with ambiguous or undermasculinized genitalia, is a genuine diagnostic puzzle. Whole-exome sequencing can identify causative mutations, but genetic results take time and not all cases yield a clear answer. A panel of blood-based markers that can be drawn during a routine hospitalization, interpreted with age-specific cutoffs, and combined with clinical findings could shorten the path to diagnosis, allow earlier initiation of appropriate hormonal therapy, and spare families months or years of uncertainty. The authors position estradiol specifically as an adjunctive marker, a supporting player that adds confidence when read together with anti-Müllerian hormone and inhibin B rather than a standalone test.

Certain caveats frame the findings appropriately. The study involved 25 affected children from a single center, and the affected group was divided into two age subgroups, so the per-group sample sizes are modest, and the reported areas under the curve will need validation in larger, multi-center cohorts before the cutoffs enter routine practice. The study also focused exclusively on male patients, since congenital hypogonadotropic hypogonadism in this cohort presented with gonadal dysfunction and genital abnormalities in boys. Nevertheless, the work opens a genuinely new angle on a stubborn diagnostic problem: it demonstrates that a hormone conventionally associated with ovarian function carries independent, quantifiable diagnostic information about the failing male axis in the very age window when clinicians have the best and perhaps only chance to act. If larger studies confirm the cutoffs, a simple estradiol measurement, already available in most clinical laboratories, could become part of the standard early workup for boys with suspicious genital findings, turning a fleeting developmental window into a genuine diagnostic opportunity.

Subject of Research: Estradiol as an adjunctive diagnostic marker for congenital hypogonadotropic hypogonadism in male infants and toddlers

Article Title: Estradiol as a potential adjunctive marker for congenital hypogonadotropic hypogonadism in infants and toddlers

Article References: Fu, D., Wu, X., Wang, H., Chen, Y., & Wei, H. (2026). Estradiol as a potential adjunctive marker for congenital hypogonadotropic hypogonadism in infants and toddlers. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07022-y

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07022-y

Keywords: congenital hypogonadotropic hypogonadism, estradiol, anti-Müllerian hormone, inhibin B, mini-puberty, hypothalamic-pituitary-gonadal axis, pediatric endocrinology, diagnostic markers, luteinizing hormone, follicle-stimulating hormone, infants, BMC Pediatrics

The research team, led by Kedir N. Turi of Indiana University with collaborators at Vanderbilt University Medical Center, UT Southwestern, and the University of Wisconsin, mined data from the Infant Susceptibility to Pulmonary Infections and Asthma following Respiratory Syncytial Virus Exposure cohort, known as INSPIRE. Between 2012 and 2014, the study enrolled 1,946 infants in the southeastern United States, of whom 1,166 could be followed to age six. Within that group, 216 children, or 18.5 percent, were diagnosed with asthma by age six using validated questionnaires that captured physician diagnoses, medication use, symptoms, steroid treatment, and acute health care visits. Rather than analyzing the entire cohort, the investigators focused on subsets with layered molecular data: 402 infants had stool microbiome profiles from 16S ribosomal RNA sequencing, 199 had urine metabolomics, and 58 had stool metabolomics. After requiring both microbiome and metabolome data plus the six-year asthma outcome, the overlapping analytical samples shrank to 89 infants for urine and 58 for stool.

Methodologically, the study is a case study in taming high-dimensional biology. The researchers first filtered rare bacterial taxa, retaining 55 amplicon sequence variants after discarding those absent from more than 90 percent of samples, and normalized microbial abundances to correct for sequencing depth. Metabolite measurements, generated with Metabolon’s untargeted ultra-high-performance liquid chromatography-tandem mass spectrometry platforms in positive, negative, and polar ionization modes, were quantile normalized, log transformed, and Pareto scaled. To identify which features actually discriminated between children who later developed asthma and those who did not, the team deployed sparse partial least squares discriminant analysis inside a nested cross-validation framework, with a stratified five-fold outer loop, ten repeats of a five-fold inner loop, and all feature selection confined strictly to training folds to prevent information leakage. Model quality was assessed by the area under the receiver operating characteristic curve, with confidence intervals estimated from 2,000 bootstrap resamples.

The discriminating power of the individual datasets was modest, and the authors are candid about that. The gut microbiome alone yielded a mean AUC of 0.55, essentially barely better than a coin flip, while urine metabolites reached 0.61 and stool metabolites 0.60. But modest prediction was not the point. The goal was to shortlist candidate features for mechanistic hypothesis generation. Among the fifteen most important microbial taxa were Eisenbergiella massiliensis, members of the Clostridium innocuum group, Thomasclavelia ramosa, unclassified Veillonella, Enterobacteriaceae, Staphylococcus, Streptococcus, and Bacteroides species, along with Bilophila wadsworthia and Collinsella aerofaciens. Enrichment analysis showed these taxa overlapped with microbial communities previously implicated in asthma, cystic fibrosis, diabetes, necrotizing colitis, and inflammatory bowel disease, although most disease-pathway terms did not survive correction for multiple testing.

The metabolite side of the ledger told an equally suggestive story. Key urinary discriminators included argininate, kynurenine, 2-methylhippurate, benzoate, and butenoylglycine, hinting at perturbations in retinol metabolism, branched-chain amino acid biosynthesis, and pantothenate and coenzyme A pathways. In stool, the standout compounds were overwhelmingly lipids: cholesterol, fructose, palmitate, myristate, the fatty acid esters of hydroxy fatty acids known as PAHSA and LAHSA, stearoyl sphingomyelin, myristoyl dihydrosphingomyelin, desmosterol, and ceramide. These point toward steroid biosynthesis, fatty acid metabolism, sphingolipid signaling, and caffeine metabolism, pathways tied to epithelial barrier function, membrane organization, and inflammatory regulation. None of the pathway enrichments remained statistically significant after false discovery rate adjustment, a limitation the researchers acknowledge, but the directional signals aligned with known asthma biology.

The heart of the paper lies in the correlations between these shortlisted taxa and metabolites, assessed with Spearman rank correlation and Bonferroni correction. Between stool bacteria and stool metabolites, the relationships were numerous and concentrated in lipid chemistry. Staphylococcus species were negatively correlated with the anti-inflammatory FAHFA lipids PAHSA and LAHSA, yet positively correlated with cholesterol and desmosterol. Enterobacteriaceae tracked with myristoyl dihydrosphingomyelin, Veillonella with stearoyl sphingomyelin, and Thomasclavelia ramosa was inversely related to ceramide. Dorea species correlated negatively with stearate, Bacteroides with 3,7-dimethylurate, and the Clostridium innocuum group with 5,6-dihydrothymine. By contrast, the cross-compartment analysis linking stool bacteria to urine metabolites was strikingly weak, with only two significant negative correlations: Collinsella aerofaciens with 2-methylhippurate and Bilophila wadsworthia with argininate.

Interpreting these patterns, the authors emphasize the ecology of the newborn gut rather than any single causal arrow. Staphylococcus is a signature genus of the early facultative-anaerobe stage of colonization and a dominant member of the breast milk microbiome, while cholesterol and desmosterol are abundant in breast milk and crucial for infant growth and immune cell function. Prior laboratory work has shown that cholesterol stimulates the proliferation of Staphylococcus species, which can scavenge host lipids to fuel growth. The observed positive correlation between the bacterium and these sterols may therefore reflect a milk-fed gut environment in which diet, microbial succession, and host lipid metabolism co-vary, rather than a direct mechanistic relationship. Similarly, the negative association between Staphylococcus and FAHFAs, lipid mediators with anti-inflammatory and immune-modulating properties that also occur in human milk, invites speculation that early colonization patterns influence the availability of these protective compounds.

The sphingolipid and purine findings reinforce the dietary thread. Sphingomyelins are among the most abundant lipids in human breast milk and infant formula, and Enterobacteriaceae and Veillonella are classic pioneer colonizers that thrive during the milk-dominated stage of infancy, so their positive correlations with sphingomyelin species may simply mark a shared developmental timeline. The inverse relationship between Bacteroides and 3,7-dimethylurate, a byproduct of xanthine and caffeine-like compounds, is particularly intriguing: xanthines reach infants through maternal caffeine passing into breast milk or through formula ingredients, while Bacteroides species, which flourish on human milk oligosaccharides and are acquired in greater abundance during vaginal birth, may accelerate the clearance of these compounds. To check whether these interpretations were plausible, the team ran the eleven significantly correlated metabolites through the MetOrigin database, which assigns putative sources. Seven were flagged as likely co-metabolised by host and microbiome, two as solely microbial, and source enrichment pointed overwhelmingly to food-derived compounds processed through microbial metabolism.

The authors are careful to frame the work as exploratory. The metabolomics subsample was deliberately enriched for early wheeze and allergic sensitization, so the discrimination metrics do not represent predictive performance in the general population. The 16S rRNA sequencing resolves bacteria only to genus level in many cases, stool sampling captures luminal rather than mucosa-associated communities, the stool metabolome subset of 58 infants is small enough that even nested cross-validation may yield unstable estimates, and no direct dietary intake data were collected, making all diet-related discussion speculative. Correlations, by definition, establish neither direction nor causation. Still, by following a longitudinally characterized birth cohort from the first months of life to a hard clinical outcome at age six, and by integrating microbiome and metabolome data from both gut and urine, the study offers a concrete, testable hypothesis: the infant gut environment shaped by feeding mode and microbial colonization produces a metabolite milieu, rich in diet-derived lipids and microbial co-metabolites, that helps calibrate the developing immune system and, in doing so, may tilt the odds toward or away from childhood asthma. Confirmation will require replication and experiments, but the biochemical suspects are now named.

Subject of Research: Integrative analysis of the infant gut microbiome and metabolome in relation to childhood asthma risk

Article Title: Exploratory integrative analysis of infant gut microbiome and metabolome suggests diet- and microbiome-derived metabolites associated with childhood asthma

Article References: Turi, K. N., Wu, X., Li, Y., Rosas-Salazar, C., Gebretsadik, T., Shilts, M. H., Das, S. R., Gern, J., Xu, Y., & Hartert, T. V. (2026). Exploratory integrative analysis of infant gut microbiome and metabolome suggests diet- and microbiome-derived metabolites associated with childhood asthma. Metabolomics, 22(5), Article 162. https://doi.org/10.1007/s11306-026-02540-3

Image Credits: AI Generated

DOI: 10.1007/s11306-026-02540-3

Keywords: asthma, gut microbiome, metabolomics, infants, birth cohort, breast milk, FAHFA lipids, sphingolipids, Staphylococcus, Bacteroides, gut-lung axis, 16S rRNA sequencing